Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.
Business briefs: GlaxoSmithKline, Adverse Event reporting, Elan
April 15, 2013
5:04 pm
GSK’s Avandia woes continue, study finds a new way to identify adverse events, and Royalty ups its bid for Elan.
Business briefs: Reps mum on adverse events; FCC’s new mHealth director; med schools tighten speaking limits
April 11, 2013
6:05 pm
A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation
Janu-“Meh”: pancreatitis study fails to cause uproar
FDA issues may deter drugmakers from engaging in social media, but that’s no excuse to ignore what audiences are saying on these platforms, say pharma and device firms.
Pfizer, AZ let clinicians query medical affairs staff via mobile phone
Drug companies are putting their in-house medical staffs on call for prescribers to ask product-related questions or report adverse events via smartphone.
Pfizer seeks ways to ease adverse events reporting digitally